UK biopharmaceutical companies experienced a surge in venture financing for innovator drugs in 2024, with total deal value doubling from 2022. This growth trend continued into Q1 2025, reaching $1.1bn.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing